These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30797713)

  • 1. Re-assessment of the high-grade serous ovarian cancer phosphoproteome - Identification of kinase candidates in TCGA tumors for future clinical intervention.
    Rolfs F; Piersma SR; Jimenez CR
    EBioMedicine; 2019 Mar; 41():34-35. PubMed ID: 30797713
    [No Abstract]   [Full Text] [Related]  

  • 2. Proteome profiling of low grade serous ovarian cancer.
    Zadeh Fakhar HB; Zali H; Rezaie-Tavirani M; Darkhaneh RF; Babaabasi B
    J Ovarian Res; 2019 Jul; 12(1):64. PubMed ID: 31315664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancer.
    Xie H; Wang W; Sun F; Deng K; Lu X; Liu H; Zhao W; Zhang Y; Zhou X; Li K; Hou Y
    Sci Rep; 2017 Aug; 7(1):9896. PubMed ID: 28852147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
    Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
    Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic analyses of serous and endometrioid epithelial ovarian cancers - cases studies - molecular insights of a possible histological etiology of serous ovarian cancer.
    Longuespée R; Gagnon H; Boyon C; Strupat K; Dauly C; Kerdraon O; Ighodaro A; Desmons A; Dupuis J; Wisztorski M; Vinatier D; Fournier I; Day R; Salzet M
    Proteomics Clin Appl; 2013 Jun; 7(5-6):337-54. PubMed ID: 23589350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.
    Hu Y; Pan J; Shah P; Ao M; Thomas SN; Liu Y; Chen L; Schnaubelt M; Clark DJ; Rodriguez H; Boja ES; Hiltke T; Kinsinger CR; Rodland KD; Li QK; Qian J; Zhang Z; Chan DW; Zhang H;
    Cell Rep; 2020 Oct; 33(3):108276. PubMed ID: 33086064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research.
    Hughes CS; McConechy MK; Cochrane DR; Nazeran T; Karnezis AN; Huntsman DG; Morin GB
    Sci Rep; 2016 Oct; 6():34949. PubMed ID: 27713570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
    Huang D; Chowdhury S; Wang H; Savage SR; Ivey RG; Kennedy JJ; Whiteaker JR; Lin C; Hou X; Oberg AL; Larson MC; Eskandari N; Delisi DA; Gentile S; Huntoon CJ; Voytovich UJ; Shire ZJ; Yu Q; Gygi SP; Hoofnagle AN; Herbert ZT; Lorentzen TD; Calinawan A; Karnitz LM; Weroha SJ; Kaufmann SH; Zhang B; Wang P; Birrer MJ; Paulovich AG
    Cell Rep Med; 2021 Dec; 2(12):100471. PubMed ID: 35028612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis, Genetics, and Genomics of Non-High Grade Serous Ovarian Cancers.
    Ilenkovan N; Gourley C
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):929-942. PubMed ID: 30390766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases.
    Kenda Šuster N; Frković Grazio S; Virant-Klun I; Verdenik I; Smrkolj Š
    Int J Gynecol Cancer; 2017 Nov; 27(9):2006-2013. PubMed ID: 28906309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients.
    Sinha D; Chong L; George J; Schlüter H; Mönchgesang S; Mills S; Li J; Parish C; Bowtell D; Kaur P;
    Clin Cancer Res; 2016 Apr; 22(7):1813-24. PubMed ID: 26589433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
    Zhang J; Wang JC; Li YH; Wang RX; Fan XM
    Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and role of glucose-regulated protein 78 in ovarian serous adenocarcinoma].
    Fan LM; Su J; Dong H; Wei M; Cui MH
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(9):659-62. PubMed ID: 23751742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
    Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
    EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    Sopo M; Sallinen H; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Anttila M
    PLoS One; 2020; 15(11):e0241484. PubMed ID: 33151982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian low-grade serous carcinoma: a comprehensive update.
    Diaz-Padilla I; Malpica AL; Minig L; Chiva LM; Gershenson DM; Gonzalez-Martin A
    Gynecol Oncol; 2012 Aug; 126(2):279-85. PubMed ID: 22555104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
    Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.